Table 2 The influence of clinical factors on the IgG APR and Ab levels against SARS-CoV-2
From: IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients
IgG APR | P-value | Mean (SD) IgG levels (S/CO) | P-value | |
|---|---|---|---|---|
Elderly group (≥ 60 years) | 71.0% | 0.88 | 4.54 (3.57) | 0.78 |
Young group (< 60years) | 69.4% | 4.78 (3.86) | ||
Male | 65.9% | 0.41 | 4.52 (3.87) | 0.80 |
Female | 74.4% | 4.86 (3.62) | ||
Vaccination group | 76.8% | 0.04 | 5.63 (3.83) | < 0.001 |
Unvaccinated group | 54.2% | 2.48 (2.32) | ||
Stage I-II lymphoma | 81.0% | 0.20 | 5.69 (3.91) | 0.17 |
Stage III-IV lymphoma | 66.1% | 4.33 (3.63) | ||
CR/PR/SD group | 71.0% | 0.62 | 4.85 (3.70) | 0.35 |
PD group | 63.6% | 3.63 (3.89) | ||
Mild COVID-19 | 71.9% | 0.55 | 5.16 (3.80) | 0.06 |
Moderate/Severe/Critical COVID-19 | 65.2% | 3.51 (3.33) | ||
Treatment for COVID-19 with dexamethasone | 55.6% | 0.32 | 2.22 (2.06) | 0.004 |
Treatment for COVID-19 without dexamethasone | 71.8% | 5.00 (3.78) | ||
Control group | 100% | -- | 9.69 (1.38) | -- |